Latest Medtech News
From wearable nerve stimulation to reduce atrial fibrillation recurrence to real-time tumour margin detection during surgery, MedTech investment is advancing more targeted approaches to treatment. Funding also supported next-generation prosthetic control, while Lucid Diagnostics reached a commercial milestone with Medicare reimbursement for its EsoGuard test.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
StimCardio raises $30M to advance wearable therapy for atrial fibrillation
StimCardio has closed an oversubscribed $30M Series A led by Metis Medtech, with participation from Catalyst Health Ventures and strategic investors. The funding will support the NeuroPulse 2 pivotal trial and FDA submission preparations for Rhyvive, a wrist-worn device delivering non-invasive nerve stimulation to reduce atrial fibrillation recurrence following catheter ablation.
CEO Amir Soltanianzadeh: "This financing brings together investors with deep expertise in cardiac device innovation and provides the resources to deliver a first-of-its-kind, multicenter pivotal study."
Lucid Diagnostics secures $15M financing as EsoGuard receives Medicare reimbursement
Lucid Diagnostics has closed a $15M Series C private placement with existing long-term shareholders and begun receiving Medicare payments for its EsoGuard Esophageal DNA Test at an established rate of $1,938.01 per test. The financing will strengthen its balance sheet and support commercial expansion of the test, which detects esophageal precancer and cancer.
CEO Lishan Aklog: "Our team is laser-focused on translating this pivotal milestone into near-term commercial results, and this financing provides the resources we need to do so."
Blue Arbor Technologies raises $10.5M to advance neuromuscular prosthetic control
Blue Arbor Technologies has raised $10.5M in a Series A led by strategic partner Ottobock. The funding will support feasibility testing, U.S. clinical studies and product development of its RESTORE™ Neuromuscular Interface System, designed to enable more intuitive, independent control of prosthetic fingers, wrists and elbows.
CEO Tod Borton: "This is a pivotal moment for Blue Arbor and for the field of prosthetic control - we are closing the gap between where the technology is today and where it needs to be for the millions of people living with limb loss."
Septal Solutions raises $7.3M through SAFE offering
Septal Solutions, formerly Excision Medical, reported $7.32 million raised from 29 investors through a SAFE offering, against a $10 million target.
Co-Founder, President & CEO Greg Walters
Dyameo raises €3M to commercialise real-time cancer detection system
French medtech company Dyameo has raised €3M, with participation from returning investors Medevice Capital and NACO, alongside Bpifrance Amorçage Industriel, OBRATORI and Estellior Capital. The funding will support production scale-up, sales team expansion and commercialisation of TempoTouch, a system designed to help surgeons assess tumour resection margins in real time during cancer surgery.
CEO Cedric Enguehard
Parasol Med Tech raises $2.75M to advance next-generation LAAO system
Parasol Med Tech raised $2.75 million from Cardiovascular Innovation Ventures, Harper Court Ventures and UChicago Medicine Ventures to advance its implant-free LAAO system. The device uses a temporary shield and gel to seal the left atrial appendage in patients with atrial fibrillation.
Founder & CMO Atman Shah: "This funding lets us take that personalized approach through the next stage of testing and closer to human patients."
Urologic Design raises $1.2M to advance urinary incontinence device
Urologic Design has raised an oversubscribed $1.2M pre-seed round led by Angel Investor Forum, with participation from HBS Alumni Angels of Boston, Haven Founders Fund, Connecticut Innovations and Yale Angels. The funding will support R&D, regulatory preparations and first-in-human study readiness for its patented urethral occlusion device designed to manage male urinary incontinence.
Co-Founder and CSO Dr. David Hesse: "We founded Urologic Design to develop a simple, temporary solution that gives people greater dignity, control, and confidence in managing leakage - all while fitting naturally into their daily lives."
CHD secures CHF 150,000 from Venture Kick to advance MONI2 maternal monitoring system
Swiss medtech startup CHD (Connected Health Development) received CHF 150,000 from Venture Kick to advance MONI2, its remote maternal and fetal monitoring system. The funding will support the development, testing and validation of functional prototypes by Q2 2027, ahead of a planned consumer launch in early 2028.
CEO Laurent Vandebrouck
Senyue Chengxing raises tens of millions of yuan in Pre-A round
Senyue Chengxing secured a Pre-A investment from Yunqi Capital to advance its SynchroMind AI algorithms, develop next-generation intelligent prosthetics and expand globally. Its Synrise S5 bionic hydraulic knee joint has entered mass production and secured over RMB 10 million in orders.
Founder & CEO Liu Derui: “The funds will be mainly used for the research and development of SynchroMind algorithm base and next-generation products, as well as global market expansion.”
GT Metabolic Solutions secures Series C investment from J.P. Morgan
GT Metabolic Solutions received an undisclosed Series C growth investment from J.P. Morgan Life Sciences Private Capital to support its global commercial launch and expansion into endoscopic and colorectal surgery. Its magnetic compression platform enables sutureless, staple-free gastrointestinal anastomoses.
Co-Founder & CEO Thierry Thaure
Nittany Angels invests $500K in BioLattice to advance engineered corneal implant
Nittany Angels committed $500,000 to BioLattice Ophthalmics as part of the company’s seed financing, marking the network’s first investment. The funding will support development of CorneaClear, an engineered corneal implant designed to provide an alternative to donor tissue for treating corneal disease.
Co-Founder & CEO Linda Alunkal
